Profund Advisors’s Ascendis Pharma A/S ASND Stock Holding History

Profund Advisors’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,536	Closed	-$379K	–	1107
2024 Q3	$379K	Sell	2,536 -383	-13%	-$51.7K	0.01%	670
2024 Q2	$398K	Buy	2,919 +85	+3%	+$11.6K	0.01%	573
2024 Q1	$428K	Sell	2,834 -397	-12%	-$56.7K	0.02%	652
2023 Q4	$407K	Buy	3,231 +691	+27%	+$68.9K	0.02%	625
2023 Q3	$238K	Sell	2,540 -151	-6%	-$14.1K	0.01%	781
2023 Q2	$240K	Sell	2,691 -514	-16%	-$44.7K	0.01%	855
2023 Q1	$344K	Buy	3,205 +245	+8%	+$28K	0.02%	652
2022 Q4	$362K	Buy	+2,960	New	+$344K	0.02%	547
2021 Q4	–	Sell	-3,124	Closed	-$498K	–	1377
2021 Q3	$498K	Buy	3,124 +133	+4%	+$18.2K	0.02%	631
2021 Q2	$393K	Buy	+2,991	New	+$399K	0.01%	837

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Profund Advisors's ASND Position: Q4 2024 in Review

Profund Advisors sold out of Ascendis Pharma A/S (ASND) in Q4 2024, closing a stake of 2,536 shares — an estimated $379K sold.

Profund Advisors first reported a position in ASND in Q2 2021 and held it in 10 quarters. The position peaked at $498K in Q3 2021. 214 funds tracked by Wall St. Rank hold ASND as of Q4 2024.

Profund Advisors reported no remaining Ascendis Pharma A/S position as of Q4 2024 after selling out during the quarter.
Profund Advisors sold 2,536 Ascendis Pharma A/S shares in Q4 2024, an estimated $379K.
Profund Advisors first reported a position in Ascendis Pharma A/S in Q2 2021 and held it in 10 quarters.
Profund Advisors's Ascendis Pharma A/S position peaked at $498K in Q3 2021.
214 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q4 2024.

Based on Profund Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.